Pfizer post-marketing site

Pfizer, has launched a website to provide up-to-date, user-friendly information on the status of its US post-marketing commitments (PMCs).

The initiative is the first of its kind for a pharmaceutical company.

PMCs are studies conducted after a medicine receives regulatory approval, generally as a requirement for approval or continued marketing of some drugs. The studies are designed to provide additional information about a treatment's safety, efficacy or optimal use.

The website provides study descriptions and status of Food and Drug Administration (FDA) post-marketing commitments, current due dates, a complete list of Pfizer PMCs, and general information about the PMC process.

The FDA first posted a database of the pharmaceutical industry's post-marketing commitments on its public-facing website in 2003. Pfizer's new site expands the information available, presented with user-friendly search functions, a glossary of terms, and frequently asked questions about PMCs.

Users can access Pfizer's regulatory commitments for prescription products using the treatment name, approval date and study status.

"From a medical compound's discovery, through its development, and for as long as it is prescribed, each of our medicines undergoes thorough safety and efficacy monitoring and evaluation in collaboration with health authorities around the world," said Pfizer's chief medical officer, Joseph Feczko.

ìThis kind of transparency helps encourage patients to ask their physicians about treatment options. When these conversations happen, they often help patients better understand the risks and benefits of different treatment options.î

The site will be updated weekly by Pfizer and can be accessed using the following link: www.pfizer.com/pmc.